transparent gif

 

Ej inloggad.

Göteborgs universitets publikationer

Alzheimer’s disease and other neurodegenerative disorders

Författare och institution:
Christoffer Rosén (Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi); Henrik Zetterberg (Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi); Kaj Blennow (Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi)
Publicerad i:
Cerebrospinal Fluid in Clinical Neurology, s. 329-351
ISBN:
978-33-19-01225-4
Publikationstyp:
Kapitel, refereegranskat
Förlag:
Springer
Publiceringsår:
2015
Språk:
engelska
Fulltextlänk:
Sammanfattning (abstract):
Traditionally, patients suffering from Alzheimer’s disease (AD) have been diagnosed according to clinical criteria, and a diagnosis has only been made in the dementia stage of the disease. Defi nite diagnosis required autopsy to confi rm the neuropathological fi ndings associated with AD, namely, extracellular depositions of amyloid a (Aa) protein and intraneuronal neurofi brillary tangles consisting of hyperphosphorylated tau (P-tau) protein, together with gross cortical atrophy caused by neuronal degeneration and loss. These fi ndings are refl ected in the cerebrospinal fl uid (CSF) of patients with AD. Numerous studies have shown that AD patients have lower levels of Aa42 and higher levels of P-tau and total tau (T-tau) in CSF than cognitively healthy controls. In the new diagnostic criteria for AD, these CSF biomarkers are included as in vivo evidence of AD neuropathology together with positron emission tomography (PET) measurements of global cortical amyloid load. Further, AD is now divided into several disease stages, namely, preclinical AD and mild cognitive impairment and dementia due to AD. In this chapter, we review CSF biomarker characteristics for the various disease stages for AD and how to use them in the differentiation against other common neurodegenerative disorders. New candidate CSF biomarkers for AD are also presented, as well as a discussion on the standardization of biomarkers and their application in clinical trials. © Springer International Publishing Switzerland 2015.
Ämne (baseras på Högskoleverkets indelning av forskningsämnen):
MEDICIN OCH HÄLSOVETENSKAP ->
Medicinska grundvetenskaper ->
Neurovetenskaper ->
Neurokemi
Postens nummer:
228357
Posten skapad:
2015-12-15 14:13
Posten ändrad:
2016-05-04 15:25

Visa i Endnote-format

Göteborgs universitet • Tel. 031-786 0000
© Göteborgs universitet 2007